Chi V Dang

List of Publications by Citations

Source: https://exaly.com/author-pdf/4325858/chi-v-dang-publications-by-citations.pdf
Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

209 papers	41,210 citations	82 h-index	203 g-index
223 ext. papers	46,574 ext. citations	11.9 avg, IF	7.89 L-index

#	Paper	IF	Citations
209	HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. *Cell Metabolism*, **2006**, 3, 177-85	24.6	2521
208	c-Myc-regulated microRNAs modulate E2F1 expression. *Nature*, **2005**, 435, 839-43	50.4	2422
207	MYC on the path to cancer. *Cell*, **2012**, 149, 22-35	56.2	1961
206	Otto Warburg's contributions to current concepts of cancer metabolism. *Nature Reviews Cancer*, **2011**, 11, 325-37	31.3	1912
205	c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. *Nature*, **2009**, 458, 762-5	50.4	1521
204	c-Myc target genes involved in cell growth, apoptosis, and metabolism. *Molecular and Cellular Biology*, **1999**, 19, 1-11	4.8	1319
203	Widespread microRNA repression by Myc contributes to tumorigenesis. *Nature Genetics*, **2008**, 40, 43-50	36.3	1083
202	Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. *Cell*, **2011**, 146, 772-84	56.2	1000
201	Cancer's molecular sweet tooth and the Warburg effect. *Cancer Research*, **2006**, 66, 8927-30	10.1	954
200	Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 2037-42	11.5	915
199	HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. *Cell*, **2007**, 129, 111-22	56.2	898
198	Oncogenic alterations of metabolism. *Trends in Biochemical Sciences*, **1999**, 24, 68-72	10.3	891
197	Development of human protein reference database as an initial platform for approaching systems biology in humans. *Genome Research*, **2003**, 13, 2363-71	9.7	823
196	The c-Myc target gene network. *Seminars in Cancer Biology*, **2006**, 16, 253-64	12.7	806
195	From Krebs to clinic: glutamine metabolism to cancer therapy. *Nature Reviews Cancer*, **2016**, 16, 619-34	31.3	796
194	Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. *Cell Metabolism*, **2012**, 15, 110-21	24.6	735
193	Links between metabolism and cancer. *Genes and Development*, **2012**, 26, 877-90	12.6	707

192	HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. *Cancer Cell*, **2007**, 11, 407-20	24.3	647
191	MYC, Metabolism, and Cancer. *Cancer Discovery*, **2015**, 5, 1024-39	24.4	627
190	MYC-induced cancer cell energy metabolism and therapeutic opportunities. *Clinical Cancer Research* , **2009**, 15, 6479-83	12.9	604
189	Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. *Cancer Cell*, **2010**, 18, 207-19	24.3	596
188	Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. *Journal of Biological Chemistry*, **2000**, 275, 21797-800	5.4	569
187	Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 19579-86	11.5	503
186	Multifaceted roles of glycolytic enzymes. *Trends in Biochemical Sciences*, **2005**, 30, 142-50	10.3	491
185	The interplay between MYC and HIF in cancer. *Nature Reviews Cancer*, **2008**, 8, 51-6	31.3	467
184	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. *Cancer Cell*, **2015**, 28, 529-540	24.3	465
183	Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. *Molecular and Cellular Biology*, **2007**, 27, 7381-93	4.8	450
182	Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. *Molecular and Cellular Biology*, **2005**, 25, 6225-34	4.8	426
181	Global mapping of c-Myc binding sites and target gene networks in human B cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 17834-9	11.5	411
180	HIF-dependent antitumorigenic effect of antioxidants in vivo. *Cancer Cell*, **2007**, 12, 230-8	24.3	410
179	MYC, metabolism, cell growth, and tumorigenesis. *Cold Spring Harbor Perspectives in Medicine*, **2013** , 3,	5.4	401
178	Drugging the QndruggableQancer targets. *Nature Reviews Cancer*, **2017**, 17, 502-508	31.3	381
177	Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. *Cancer Research*, **2010**, 70, 8981-7	10.1	380
176	An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. *Genome Biology*, **2003**, 4, R69	18.3	378
175	Translocations involving c-myc and c-myc function. *Oncogene*, **2001**, 20, 5595-610	9.2	365

174	Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 8983-8	11.5	325
173	Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 3384-9	11.5	319
172	Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. *Blood*, **2009**, 114, 5473-80	2.2	314
171	Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. *Cancer Research*, **2010**, 70, 859-62	10.1	312
170	c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. *Journal of Biological Chemistry*, **1995**, 270, 18961-5	5.4	303
169	Function of the c-Myc oncogenic transcription factor. *Experimental Cell Research*, **1999**, 253, 63-77	4.2	297
168	Hypoxia inhibits G1/S transition through regulation of p27 expression. *Journal of Biological Chemistry*, **2001**, 276, 7919-26	5.4	277
167	Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. *Molecular and Cellular Biology*, **1999**, 19, 5696-706	4.8	265
166	Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. *Nature Genetics*, **2010**, 42, 840-50	36.3	257
165	Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. *Journal of Clinical Investigation*, **2015**, 125, 2293-306	15.9	251
164	Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. *Molecular and Cellular Biology*, **2004**, 24, 5923-36	4.8	248
163	Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis. *Cancer Research*, **2014**, 74, 908-20	10.1	219
162	Involvement of the Qleucine zipperQregion in the oligomerization and transforming activity of human c-myc protein. *Nature*, **1989**, 337, 664-6	50.4	198
161	Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 4578-83	11.5	192
160	MYC and metabolism on the path to cancer. *Seminars in Cell and Developmental Biology*, **2015**, 43, 11-21	7.5	191
159	MYC and Prostate Cancer. *Genes and Cancer*, **2010**, 1, 617-28	2.9	191
158	Global regulation of nucleotide biosynthetic genes by c-Myc. *PLoS ONE*, **2008**, 3, e2722	3.7	187
157	Glutaminolysis: supplying carbon or nitrogen or both for cancer cells?. *Cell Cycle*, **2010**, 9, 3884-6	4.7	183

156	Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. *Nature Structural and Molecular Biology*, **2016**, 23, 522-30	17.6	183
155	Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. *Journal of Neuropathology and Experimental Neurology*, **2004**, 63, 441-9	3.1	177
154	Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. *Molecular and Cellular Biology*, **2006**, 26, 2373-86	4.8	174
153	The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 6649-54	11.5	156
152	MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. *Cell Metabolism*, **2015**, 22, 1009-19	24.6	152
151	Function of the c-Myc oncoprotein. *FASEB Journal*, **1992**, 6, 3065-72	0.9	142
150	MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 6539-44	11.5	139
149	Therapeutic targeting of cancer cell metabolism. *Journal of Molecular Medicine*, **2011**, 89, 205-12	5.5	133
148	Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. *Journal of Medicinal Chemistry*, **2012**, 55, 10551-63	8.3	129
147	Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. *Science Translational Medicine*, **2017**, 9,	17.5	121
146	Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. *PLoS ONE*, **2011**, 6, e26057	3.7	114
145	Identification of a large Myc-binding protein that contains RCC1-like repeats. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 9172-7	11.5	114
144	c-Myc overexpression uncouples DNA replication from mitosis. *Molecular and Cellular Biology*, **1999**, 19, 5339-51	4.8	114
143	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. *Experimental Hematology*, **2014**, 42, 247-51	3.1	107
142	17beta-estradiol inhibits apoptosis of endothelial cells. *Biochemical and Biophysical Research Communications*, **1997**, 237, 372-81	3.4	107
141	Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. *Cancer Research*, **2015**, 75, 3355-64	10.1	106
140	Effects of hypoxia on tumor metabolism. *Cancer and Metastasis Reviews*, **2007**, 26, 291-8	9.6	105
139	Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR. *Cell*, **2018**, 174, 72-87.e32	56.2	104

138	c-myc overexpression causes anaplasia in medulloblastoma. *Cancer Research*, **2006**, 66, 673-81	10.1	103
137	Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. *Clinical Cancer Research*, **2015**, 21, 3263-73	12.9	100
136	MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. *PLoS ONE*, **2010**, 5, e9427	3.7	99
135	Clock Regulation of Metabolites Reveals Coupling between Transcription and Metabolism. *Cell Metabolism*, **2017**, 25, 961-974.e4	24.6	96
134	The role of long noncoding RNAs in cancer: the dark matter matters. *Current Opinion in Genetics and Development*, **2018**, 48, 8-15	4.9	96
133	Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation. *Journal of Biological Chemistry*, **2001**, 276, 48285-91	5.4	94
132	Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. *Journal of Bioenergetics and Biomembranes*, **1997**, 29, 345-54	3.7	89
131	A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 5313-8	11.5	89
130	The great MYC escape in tumorigenesis. *Cancer Cell*, **2005**, 8, 177-8	24.3	87
129	Elevated extracellular calcium can prevent apoptosis via the calcium-sensing receptor. *Biochemical and Biophysical Research Communications*, **1998**, 249, 325-31	3.4	85
128	Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. *American Journal of Pathology*, **2011**, 178, 1824-34	5.8	82
127	Arsenic inhibition of telomerase transcription leads to genetic instability. *Journal of Clinical Investigation*, **2001**, 108, 1541-7	15.9	81
126	MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. *Cancer Research*, **2018**, 78, 64-74	10.1	76
125	Isotopically nonstationary 13C flux analysis of Myc-induced metabolic reprogramming in B-cells. *Metabolic Engineering*, **2013**, 15, 206-17	9.7	75
124	Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress. *Cell Research*, **2016**, 26, 1112-1130	24.7	71
123	A nontranscriptional role for HIF-1 as a direct inhibitor of DNA replication. *Science Signaling*, **2013**, 6, ra10	8.8	69
122	Biology and treatment of Burkitt lymphoma. *Current Opinion in Hematology*, **2007**, 14, 375-81	3.3	68
121	Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. *Journal of the American Association for Laboratory Animal Science*, **2008**, 47, 37-40	1.3	68

120	Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). *Journal of Medicinal Chemistry*, **2017**, 60, 9184-9204	8.3	67
119	Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. *Blood*, **2005**, 106, 304-10	2.2	66
118	Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy. *Trends in Cell Biology*, **2018**, 28, 201-212	18.3	65
117	Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. *Current Opinion in Hematology*, **2005**, 12, 1-6	3.3	63
116	A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. *Nature Cell Biology*, **2018**, 20, 104-115	23.4	63
115	hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. *American Journal of Pathology*, **2003**, 162, 1763-9	5.8	62
114	IRE1RNase-dependent lipid homeostasis promotes survival in Myc-transformed cancers. *Journal of Clinical Investigation*, **2018**, 128, 1300-1316	15.9	58
113	EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect. *Oncotarget*, **2017**, 8, 9557-9571	3.3	57
112	Unique conformation of cancer autoantigen B23 in hepatoma: a mechanism for specificity in the autoimmune response. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 12361-6	11.5	56
111	An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis. *Cancer Cell*, **2015**, 28, 472-485	24.3	55
110	Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors. *Cancer Research*, **2013**, 73, 4190-5	10.1	55
109	PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg effect. *Science Signaling*, **2009**, 2, pe75	8.8	53
108	Increased expression of TATA-binding protein, the central transcription factor, can contribute to oncogenesis. *Molecular and Cellular Biology*, **2003**, 23, 3043-51	4.8	53
107	The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth. *Cell Metabolism*, **2019**, 30, 556-572.e5	24.6	52
106	Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. *Clinical Cancer Research*, **2017**, 23, 5639-5647	12.9	50
105	Conceptual framework for cutting the pancreatic cancer fuel supply. *Clinical Cancer Research*, **2012**, 18, 4285-90	12.9	48
104	Enigmatic MYC Conducts an Unfolding Systems Biology Symphony. *Genes and Cancer*, **2010**, 1, 526-531	2.9	47
103	High molecular mass amino acyl-tRNA synthetase complexes in eukaryotes. *FEBS Letters*, **1982**, 142, 1-6	3.8	47

102	The normal and morbid biology of fibrinogen. *American Journal of Medicine*, **1989**, 87, 567-76	2.4	46
101	Normal and cancer cell metabolism: lymphocytes and lymphoma. *FEBS Journal*, **2012**, 279, 2598-609	5.7	45
100	Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. *Proceedings of the National Academy of Sciences of the United States of America* , **2010**, 107, 3534-9	11.5	45
99	The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo. *Cancer Research*, **2005**, 65, 5620-7	10.1	43
98	Isolation of bone marrow-derived stem cells using density-gradient separation. *Experimental Hematology*, **2007**, 35, 335-41	3.1	42
97	Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability?. *Cell Cycle*, **2005**, 4, 1465-6	4.7	42
96	A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation. *Journal of Biological Chemistry*, **2001**, 276, 48276-84	5.4	42
95	Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxia-cell cycle dual reporter. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 12486-91	11.5	39
94	Cyclin A links c-Myc to adhesion-independent cell proliferation. *Journal of Biological Chemistry*, **1995**, 270, 15923-5	5.4	37
93	Mammalian BUB1 protein kinases: map positions and in vivo expression. *Genomics*, **1997**, 46, 379-88	4.3	35
92	Rat liver histidyl-tRNA synthetase. Purification and inhibition by the myositis-specific anti-Jo-1 autoantibody. *Biochemical and Biophysical Research Communications*, **1984**, 120, 15-21	3.4	35
91	Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma". *Clinical Cancer Research*, **2017**, 23, 1629-1637	12.9	33
90	Conditional deletion of c-myc does not impair liver regeneration. *Cancer Research*, **2006**, 66, 5608-12	10.1	33
89	synthesis of serine and glycine fuels purine nucleotide biosynthesis in human lung cancer tissues. *Journal of Biological Chemistry*, **2019**, 294, 13464-13477	5.4	32
88	p32 (C1QBP) and cancer cell metabolism: is the Warburg effect a lot of hot air?. *Molecular and Cellular Biology*, **2010**, 30, 1300-2	4.8	32
87	Targeting cancer metabolism in the era of precision oncology. *Nature Reviews Drug Discovery*, **2021**,	64.1	32
86	Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy. *Cell Reports*, **2020**, 30, 1798-1810.e4	10.6	32
85	A Time for MYC: Metabolism and Therapy. *Cold Spring Harbor Symposia on Quantitative Biology*, **2016**, 81, 79-83	3.9	31

84	The c-Myc target gene Rcl (C6orf108) encodes a novel enzyme, deoxynucleoside 5-monophosphate N-glycosidase. *Journal of Biological Chemistry*, **2007**, 282, 8150-6	5.4	30
83	Evidence for involvement of calpain in c-Myc proteolysis in vivo. *Archives of Biochemistry and Biophysics*, **2002**, 400, 151-61	4.1	30
82	Genomic organization of human MXI1, a putative tumor suppressor gene. *Genomics*, **1996**, 32, 466-70	4.3	30
81	Role of Oncogenic Transcription Factor c-Myc in Cell Cycle Regulation, Apoptosis and Metabolism. *Journal of Biomedical Science*, **1997**, 4, 269-278	13.3	29
80	Cancer genetics: tumor suppressor meets oncogene. *Current Biology*, **1999**, 9, R62-5	6.3	29
79	Localization of the human Mxi1 transcription factor gene (MXI1) to chromosome 10q24-q25. *Genomics*, **1994**, 21, 669-72	4.3	29
78	High molecular weight complexes of eukaryotic aminoacyl-tRNA synthetases. *International Journal of Biochemistry & Cell Biology*, **1982**, 14, 539-43		29
77	Time-dependent c-Myc transactomes mapped by Array-based nuclear run-on reveal transcriptional modules in human B cells. *PLoS ONE*, **2010**, 5, e9691	3.7	27
76	Human T-cell leukemia virus type I tax masks c-Myc function through a cAMP-dependent pathway. *Journal of Biological Chemistry*, **1996**, 271, 9730-8	5.4	26
75	Multienzyme complexes of eukaryotic aminoacyl-tRNA synthetases. *Bioscience Reports*, **1983**, 3, 527-38	4.1	26
74	Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 1816-1823	6.1	26
73	Stress eating and tuning out: cancer cells re-wire metabolism to counter stress. *Critical Reviews in Biochemistry and Molecular Biology*, **2013**, 48, 609-19	8.7	25
72	Identification and characterization of the novel centrosome-associated protein CCCAP. *Gene*, **2003**, 303, 35-46	3.8	25
71	In silico identification of transcriptional regulators associated with c-Myc. *Nucleic Acids Research*, **2004**, 32, 4955-61	20.1	23
70	Studying Myc role in metabolism regulation. *Methods in Molecular Biology*, **2013**, 1012, 213-9	1.4	23
69	Tobacco-alcohol amblyopia: a proposed biochemical basis for pathogenesis. *Medical Hypotheses*, **1981**, 7, 1317-28	3.8	22
68	Antimalarial therapy prevents Myc-induced lymphoma. *Journal of Clinical Investigation*, **2008**, 118, 15-7	15.9	22
67	c-myc oncoprotein function. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1991**, 1072, 103-13	11.2	21

66	MYC, Metabolic Synthetic Lethality, and Cancer. *Recent Results in Cancer Research*, **2016**, 207, 73-91	1.5	20
65	Gene regulation: fine-tuned amplification in cells. *Nature*, **2014**, 511, 417-8	50.4	20
64	Cancer cell metabolism: there is no ROS for the weary. *Cancer Discovery*, **2012**, 2, 304-7	24.4	20
63	Anoxic fibroblasts activate a replication checkpoint that is bypassed by E1a. *Molecular and Cellular Biology*, **2003**, 23, 9032-45	4.8	20
62	MYC-induced metabolic stress and tumorigenesis. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2018**, 1870, 43-50	11.2	20
61	MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. *Blood Cells, Molecules, and Diseases*, **2013**, 50, 190-5	2.1	19
60	Discovering robust protein biomarkers for disease from relative expression reversals in 2-D DIGE data. *Proteomics*, **2007**, 7, 1197-207	4.8	19
59	A metabolic perspective of Peto's paradox and cancer. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2015**, 370,	5.8	18
58	The Ketogenic Diet Does Not Affect Growth of Hedgehog Pathway Medulloblastoma in Mice. *PLoS ONE*, **2015**, 10, e0133633	3.7	18
57	A strategy to identify differentially expressed genes using representational difference analysis and cDNA arrays. *Analytical Biochemistry*, **2001**, 288, 141-148	3.1	18
56	Interactions of aminoacyl-tRNA synthetases in high-molecular-weight multienzyme complexes from rat liver. *BBA - Proteins and Proteomics*, **1985**, 829, 319-26		18
55	Oncogenic alterations of metabolism and the Warburg effect. *Drug Discovery Today Disease Mechanisms*, **2005**, 2, 233-238		17
54	c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli. *Oncogene*, **2001**, 20, 6084-94	9.2	17
53	Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis. *Molecular and Cellular Biology*, **2019**, 39,	4.8	16
52	Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth. *Journal of Biological Chemistry*, **2019**, 294, 10407-10414	5.4	16
51	Histidyl-tRNA synthetase, the myositis Jo-1 antigen, is cytoplasmic and unassociated with the cytoskeletal framework. *Experimental Cell Research*, **1986**, 164, 261-6	4.2	14
50	Metabolic and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in breast cancer cells. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 7057-62	3.4	12
49	c-Myc Function in Neoplasia. *Medical Intelligence Unit*, **1995**,		12

48	Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties. *Journal of Medicinal Chemistry*, **2020**, 63, 10984-11011	8.3	12
47	Web of the extended Myc network captures metabolism for tumorigenesis. *Cancer Cell*, **2015**, 27, 160-2	24.3	11
46	ChIP-PED enhances the analysis of ChIP-seq and ChIP-chip data. *Bioinformatics*, **2013**, 29, 1182-9	7.2	11
45	Protective effect of divalent cations in the plasmin degradation of fibrinogen. *Archives of Biochemistry and Biophysics*, **1985**, 238, 452-7	4.1	11
44	Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. *Leukemia*, **2019**, 33, 2429-2441	10.7	10
43	Splicing and Dicing MYC-Mediated Synthetic Lethality. *Cancer Cell*, **2015**, 28, 405-406	24.3	10
42	Application of a nitrocellulose immunoassay for quantitation of proteins secreted in culture media. *Analytical Biochemistry*, **1986**, 158, 262-7	3.1	10
41	High molecular weight complex formation of rat liver lysyl-tRNA synthetase reduces enzyme lability to thermal inactivation. *Biochemical and Biophysical Research Communications*, **1982**, 106, 44-7	3.4	10
40	Correspondence: Oncogenic MYC persistently upregulates the molecular clock component REV-ERB *Nature Communications*, **2017**, 8, 14862	17.4	9
39	Role of aerobic glycolysis in genetically engineered mouse models of cancer. *BMC Biology*, **2013**, 11, 3	7.3	9
38	Stimulation of Myc transactivation by the TATA binding protein in promoter-reporter assays. *BMC Biochemistry*, **2005**, 6, 7	4.8	9
37	c-myc Protooncogene **2002**, 555-561		9
36	Hydrodynamic properties and structure of the rat liver 12 S arginyl- and lysyl-tRNA synthetase complex. *Biochemical and Biophysical Research Communications*, **1983**, 117, 464-9	3.4	8
35	Feeding frenzy for cancer cells. *Science*, **2017**, 358, 862-863	33.3	7
34	Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation. *Cancer Cell*, **2010**, 18, 397	24.3	7
33	A case of agnogenic myeloid metaplasia evolving into acute myelogenous leukemia associated with the development of trisomy 11 in bone marrow cells. *American Journal of Hematology*, **1985**, 19, 285-8	7.1	7
32	Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. *Cancer Research*, **2021**, 81, 1627-1632	10.1	7
31	Array-based nuclear run-on analysis. *Methods in Molecular Biology*, **2012**, 809, 505-17	1.4	6

30	Have you seen...?: Micro-managing and restraining pluripotent stem cells by MYC. *EMBO Journal*, **2009**, 28, 3065-6	13	5
29	c-MYC mRNA tail tale about glutamine control of transcription. *EMBO Journal*, **2017**, 36, 1806-1808	13	4
28	Turning publicly available gene expression data into discoveries using gene set context analysis. *Nucleic Acids Research*, **2016**, 44, e8	20.1	4
27	MUC-king with HIF May Rewire Pyrimidine Biosynthesis and Curb Gemcitabine Resistance in Pancreatic Cancer. *Cancer Cell*, **2017**, 32, 3-5	24.3	4
26	Detection and use of recombinant staphylococcal protein A fusion proteins to localize nucleic-acid-binding domains of proteins. *Analytical Biochemistry*, **1988**, 174, 313-7	3.1	4
25	Myoglobin tames tumor growth and spread. *Journal of Clinical Investigation*, **2009**, 119, 766-8	15.9	4
24	Glutamine Skipping the Q into Mitochondria. *Trends in Molecular Medicine*, **2020**, 26, 6-7	11.5	4
23	mTOR Senses Intracellular pH through Lysosome Dispersion from RHEB. *BioEssays*, **2019**, 41, e1800265	4.1	3
22	Epigenetic state determines inflammatory sensing in neuroblastoma.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119,	11.5	3
21	Autophagy: clocking in for the night shift. *EMBO Journal*, **2019**, 38,	13	2
20	Heparin requirement for the quantitation of fibrinogen production by primary hepatocyte cultures. *Analytical Biochemistry*, **1988**, 170, 456-62	3.1	2
19	Misregulation of Drosophila Myc Disrupts Circadian Behavior and Metabolism. *Cell Reports*, **2019**, 29, 1778-1788.e4	10.6	2
18	Role of Oncogenic Transcription Factor c-Myc in Cell Cycle Regulation, Apoptosis and Metabolism. *Journal of Biomedical Science*, **1997**, 4, 269-278	13.3	1
17	Muscle fatigue from losing your PHD. *Cell Metabolism*, **2008**, 7, 191-2	24.6	1
16	Intranuclear location of the myositis-specific Jo-1 antigen: hopping histidyl-tRNA synthetase?. *Arthritis and Rheumatism*, **1985**, 28, 839-40		1
15	MYC Regulation of Metabolism and Cancer **2015**, 101-122		1
14	ORGANIZATION OF MAMMALIAN AMINOACYL-tRNA SYNTHETASES **1978**, 575-580		1
13	Myc and Control of Tumor Neovascularization **2010**, 167-187		1

12	Tilting MYC toward cancer cell death. *Trends in Cancer*, **2021**, 7, 982-994	12.5	1
11	Measuring MYC-Mediated Metabolism in Tumorigenesis. *Methods in Molecular Biology*, **2021**, 2318, 231-239	2.4	1
10	Celebrating the physician-scientist. *Journal of Clinical Investigation*, **2003**, 112, S1-2	15.9	1
9	Essentiality of non-essential amino acids for tumour cells and tumorigenesis. *Nature Metabolism*, **2019**, 1, 847-848	14.6	0
8	Sex, life, and death in MYC-driven lymphomagenesis. *Molecular Cell*, **2021**, 81, 3886-3887	17.6	0
7	Peer Review: Value Added and Civility.. *Cancer Research*, **2022**, 82, 1157-1158	10.1	0
6	Edging toward new therapeutics with cyclin D1 Egl@g on cancer. *Cancer Cell*, **2009**, 16, 361-2	24.3	
5	Myc Target Genes in Cell Proliferation and Programmed Cell Death. *Medical Intelligence Unit*, **1995**, 171-192		
4	Max Association with Myc. *Medical Intelligence Unit*, **1995**, 151-163		
3	Properties of the c-Myc Protein. *Medical Intelligence Unit*, **1995**, 109-118		
2	Pancytopenia Secondary to Oxalosis in a 23-Year-Old Woman. *Blood*, **1998**, 91, 4394-4394	2.2	
1	Differential Regulation of MicroRNA Expression In Polycythemia Vera CD34+ Cells. *Blood*, **2010**, 116, 4785-4785	2.2	